nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP2D6—Alzheimer's disease	0.295	1	CbGaD
Vemurafenib—CYP2D6—Rivastigmine—Alzheimer's disease	0.095	0.264	CbGbCtD
Vemurafenib—CYP2D6—Donepezil—Alzheimer's disease	0.076	0.211	CbGbCtD
Vemurafenib—CYP3A4—Rivastigmine—Alzheimer's disease	0.0604	0.168	CbGbCtD
Vemurafenib—CYP2D6—Galantamine—Alzheimer's disease	0.049	0.136	CbGbCtD
Vemurafenib—CYP3A4—Donepezil—Alzheimer's disease	0.0483	0.134	CbGbCtD
Vemurafenib—CYP3A4—Galantamine—Alzheimer's disease	0.0311	0.0865	CbGbCtD
Vemurafenib—Common wart—Rivastigmine—Alzheimer's disease	0.00914	0.0525	CcSEcCtD
Vemurafenib—Squamous cell carcinoma—Memantine—Alzheimer's disease	0.00597	0.0343	CcSEcCtD
Vemurafenib—Basal cell carcinoma—Memantine—Alzheimer's disease	0.00575	0.033	CcSEcCtD
Vemurafenib—Basal cell carcinoma—Rivastigmine—Alzheimer's disease	0.00563	0.0323	CcSEcCtD
Vemurafenib—Hyperkeratosis—Donepezil—Alzheimer's disease	0.00522	0.03	CcSEcCtD
Vemurafenib—Electrocardiogram QT corrected interval prolonged—Memantine—Alzheimer's disease	0.00503	0.0289	CcSEcCtD
Vemurafenib—Hyperkeratosis—Memantine—Alzheimer's disease	0.00474	0.0272	CcSEcCtD
Vemurafenib—Hyperkeratosis—Rivastigmine—Alzheimer's disease	0.00464	0.0267	CcSEcCtD
Vemurafenib—Sunburn—Rivastigmine—Alzheimer's disease	0.00439	0.0252	CcSEcCtD
Vemurafenib—Skin papilloma—Rivastigmine—Alzheimer's disease	0.00407	0.0234	CcSEcCtD
Vemurafenib—Electrocardiogram QT prolonged—Galantamine—Alzheimer's disease	0.003	0.0172	CcSEcCtD
Vemurafenib—Cyst—Donepezil—Alzheimer's disease	0.00223	0.0128	CcSEcCtD
Vemurafenib—Electrocardiogram QT prolonged—Memantine—Alzheimer's disease	0.00211	0.0121	CcSEcCtD
Vemurafenib—Electrocardiogram QT prolonged—Rivastigmine—Alzheimer's disease	0.00207	0.0119	CcSEcCtD
Vemurafenib—Paralysis—Memantine—Alzheimer's disease	0.00195	0.0112	CcSEcCtD
Vemurafenib—Rigors—Memantine—Alzheimer's disease	0.00166	0.00954	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Memantine—Alzheimer's disease	0.00165	0.00946	CcSEcCtD
Vemurafenib—Rigors—Rivastigmine—Alzheimer's disease	0.00162	0.00933	CcSEcCtD
Vemurafenib—Neoplasm malignant—Rivastigmine—Alzheimer's disease	0.00155	0.00892	CcSEcCtD
Vemurafenib—Etoricoxib—CYP2D6—Alzheimer's disease	0.0015	0.544	CrCbGaD
Vemurafenib—Atrial fibrillation—Galantamine—Alzheimer's disease	0.00148	0.00848	CcSEcCtD
Vemurafenib—Arthritis—Galantamine—Alzheimer's disease	0.00144	0.00826	CcSEcCtD
Vemurafenib—Pain in extremity—Galantamine—Alzheimer's disease	0.0014	0.00803	CcSEcCtD
Vemurafenib—Vasculitis—Rivastigmine—Alzheimer's disease	0.00136	0.0078	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—Alzheimer's disease	0.00126	0.456	CrCbGaD
Vemurafenib—Neoplasm—Memantine—Alzheimer's disease	0.00123	0.00704	CcSEcCtD
Vemurafenib—Rash maculo-papular—Rivastigmine—Alzheimer's disease	0.00121	0.00692	CcSEcCtD
Vemurafenib—Neoplasm—Rivastigmine—Alzheimer's disease	0.0012	0.00689	CcSEcCtD
Vemurafenib—Atrial fibrillation—Donepezil—Alzheimer's disease	0.00114	0.00657	CcSEcCtD
Vemurafenib—Arthritis—Donepezil—Alzheimer's disease	0.00112	0.0064	CcSEcCtD
Vemurafenib—RAF1—embryo—Alzheimer's disease	0.00111	0.107	CbGeAlD
Vemurafenib—Weight decreased—Galantamine—Alzheimer's disease	0.00109	0.00628	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Galantamine—Alzheimer's disease	0.00106	0.00607	CcSEcCtD
Vemurafenib—Atrial fibrillation—Memantine—Alzheimer's disease	0.00104	0.00596	CcSEcCtD
Vemurafenib—Atrial fibrillation—Rivastigmine—Alzheimer's disease	0.00102	0.00583	CcSEcCtD
Vemurafenib—Arthritis—Memantine—Alzheimer's disease	0.00101	0.00581	CcSEcCtD
Vemurafenib—Dry skin—Donepezil—Alzheimer's disease	0.000993	0.00571	CcSEcCtD
Vemurafenib—Arthritis—Rivastigmine—Alzheimer's disease	0.000991	0.00569	CcSEcCtD
Vemurafenib—Pain in extremity—Memantine—Alzheimer's disease	0.000984	0.00565	CcSEcCtD
Vemurafenib—RAF1—forebrain—Alzheimer's disease	0.000978	0.0951	CbGeAlD
Vemurafenib—Pain in extremity—Rivastigmine—Alzheimer's disease	0.000963	0.00553	CcSEcCtD
Vemurafenib—Oedema peripheral—Galantamine—Alzheimer's disease	0.000953	0.00547	CcSEcCtD
Vemurafenib—Connective tissue disorder—Galantamine—Alzheimer's disease	0.000951	0.00546	CcSEcCtD
Vemurafenib—Eosinophilia—Donepezil—Alzheimer's disease	0.000927	0.00533	CcSEcCtD
Vemurafenib—Eye disorder—Galantamine—Alzheimer's disease	0.000904	0.00519	CcSEcCtD
Vemurafenib—Dry skin—Memantine—Alzheimer's disease	0.000902	0.00518	CcSEcCtD
Vemurafenib—RAF1—telencephalon—Alzheimer's disease	0.000899	0.0874	CbGeAlD
Vemurafenib—Cardiac disorder—Galantamine—Alzheimer's disease	0.000898	0.00516	CcSEcCtD
Vemurafenib—Dry skin—Rivastigmine—Alzheimer's disease	0.000882	0.00507	CcSEcCtD
Vemurafenib—Angiopathy—Galantamine—Alzheimer's disease	0.000878	0.00504	CcSEcCtD
Vemurafenib—Weight decreased—Donepezil—Alzheimer's disease	0.000847	0.00487	CcSEcCtD
Vemurafenib—Malnutrition—Galantamine—Alzheimer's disease	0.000842	0.00484	CcSEcCtD
Vemurafenib—Infestation—Donepezil—Alzheimer's disease	0.000835	0.0048	CcSEcCtD
Vemurafenib—Infestation NOS—Donepezil—Alzheimer's disease	0.000835	0.0048	CcSEcCtD
Vemurafenib—Dysgeusia—Galantamine—Alzheimer's disease	0.000825	0.00474	CcSEcCtD
Vemurafenib—Back pain—Galantamine—Alzheimer's disease	0.000815	0.00468	CcSEcCtD
Vemurafenib—Weight decreased—Memantine—Alzheimer's disease	0.000769	0.00442	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Rivastigmine—Alzheimer's disease	0.000759	0.00436	CcSEcCtD
Vemurafenib—Infestation—Memantine—Alzheimer's disease	0.000758	0.00436	CcSEcCtD
Vemurafenib—Infestation NOS—Memantine—Alzheimer's disease	0.000758	0.00436	CcSEcCtD
Vemurafenib—Weight decreased—Rivastigmine—Alzheimer's disease	0.000753	0.00432	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Memantine—Alzheimer's disease	0.000752	0.00432	CcSEcCtD
Vemurafenib—BRAF—cerebellum—Alzheimer's disease	0.00075	0.0729	CbGeAlD
Vemurafenib—Neuropathy peripheral—Memantine—Alzheimer's disease	0.000743	0.00427	CcSEcCtD
Vemurafenib—Infestation—Rivastigmine—Alzheimer's disease	0.000742	0.00426	CcSEcCtD
Vemurafenib—Infestation NOS—Rivastigmine—Alzheimer's disease	0.000742	0.00426	CcSEcCtD
Vemurafenib—Oedema peripheral—Donepezil—Alzheimer's disease	0.000739	0.00424	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Rivastigmine—Alzheimer's disease	0.000736	0.00422	CcSEcCtD
Vemurafenib—Cough—Galantamine—Alzheimer's disease	0.000735	0.00422	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Rivastigmine—Alzheimer's disease	0.000727	0.00418	CcSEcCtD
Vemurafenib—Arthralgia—Galantamine—Alzheimer's disease	0.000717	0.00412	CcSEcCtD
Vemurafenib—Myalgia—Galantamine—Alzheimer's disease	0.000717	0.00412	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.000712	0.00409	CcSEcCtD
Vemurafenib—Nervous system disorder—Galantamine—Alzheimer's disease	0.000674	0.00387	CcSEcCtD
Vemurafenib—Chills—Donepezil—Alzheimer's disease	0.000673	0.00386	CcSEcCtD
Vemurafenib—Oedema peripheral—Memantine—Alzheimer's disease	0.000671	0.00385	CcSEcCtD
Vemurafenib—Connective tissue disorder—Memantine—Alzheimer's disease	0.000669	0.00384	CcSEcCtD
Vemurafenib—Skin disorder—Galantamine—Alzheimer's disease	0.000668	0.00383	CcSEcCtD
Vemurafenib—Alopecia—Donepezil—Alzheimer's disease	0.000663	0.00381	CcSEcCtD
Vemurafenib—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.000656	0.00377	CcSEcCtD
Vemurafenib—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.000654	0.00376	CcSEcCtD
Vemurafenib—Erythema—Donepezil—Alzheimer's disease	0.000653	0.00375	CcSEcCtD
Vemurafenib—Malnutrition—Donepezil—Alzheimer's disease	0.000653	0.00375	CcSEcCtD
Vemurafenib—Erythema multiforme—Memantine—Alzheimer's disease	0.000644	0.0037	CcSEcCtD
Vemurafenib—Hypotension—Galantamine—Alzheimer's disease	0.000642	0.00369	CcSEcCtD
Vemurafenib—Dysgeusia—Donepezil—Alzheimer's disease	0.000639	0.00367	CcSEcCtD
Vemurafenib—Eye disorder—Memantine—Alzheimer's disease	0.000636	0.00365	CcSEcCtD
Vemurafenib—Cardiac disorder—Memantine—Alzheimer's disease	0.000632	0.00363	CcSEcCtD
Vemurafenib—Back pain—Donepezil—Alzheimer's disease	0.000631	0.00363	CcSEcCtD
Vemurafenib—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.00063	0.00362	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000626	0.0036	CcSEcCtD
Vemurafenib—Eye disorder—Rivastigmine—Alzheimer's disease	0.000622	0.00357	CcSEcCtD
Vemurafenib—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000618	0.00355	CcSEcCtD
Vemurafenib—Angiopathy—Memantine—Alzheimer's disease	0.000618	0.00355	CcSEcCtD
Vemurafenib—Mediastinal disorder—Memantine—Alzheimer's disease	0.000614	0.00352	CcSEcCtD
Vemurafenib—Chills—Memantine—Alzheimer's disease	0.000611	0.00351	CcSEcCtD
Vemurafenib—BRAF—brain—Alzheimer's disease	0.000609	0.0592	CbGeAlD
Vemurafenib—Angiopathy—Rivastigmine—Alzheimer's disease	0.000604	0.00347	CcSEcCtD
Vemurafenib—Alopecia—Memantine—Alzheimer's disease	0.000602	0.00345	CcSEcCtD
Vemurafenib—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.0006	0.00345	CcSEcCtD
Vemurafenib—Chills—Rivastigmine—Alzheimer's disease	0.000598	0.00343	CcSEcCtD
Vemurafenib—Decreased appetite—Galantamine—Alzheimer's disease	0.000598	0.00343	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000593	0.00341	CcSEcCtD
Vemurafenib—Malnutrition—Memantine—Alzheimer's disease	0.000593	0.0034	CcSEcCtD
Vemurafenib—Fatigue—Galantamine—Alzheimer's disease	0.000593	0.0034	CcSEcCtD
Vemurafenib—Alopecia—Rivastigmine—Alzheimer's disease	0.000589	0.00338	CcSEcCtD
Vemurafenib—Constipation—Galantamine—Alzheimer's disease	0.000588	0.00338	CcSEcCtD
Vemurafenib—Dysgeusia—Memantine—Alzheimer's disease	0.00058	0.00333	CcSEcCtD
Vemurafenib—Malnutrition—Rivastigmine—Alzheimer's disease	0.00058	0.00333	CcSEcCtD
Vemurafenib—Erythema—Rivastigmine—Alzheimer's disease	0.00058	0.00333	CcSEcCtD
Vemurafenib—Back pain—Memantine—Alzheimer's disease	0.000573	0.00329	CcSEcCtD
Vemurafenib—Cough—Donepezil—Alzheimer's disease	0.00057	0.00327	CcSEcCtD
Vemurafenib—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000568	0.00326	CcSEcCtD
Vemurafenib—Back pain—Rivastigmine—Alzheimer's disease	0.000561	0.00322	CcSEcCtD
Vemurafenib—Arthralgia—Donepezil—Alzheimer's disease	0.000556	0.00319	CcSEcCtD
Vemurafenib—Myalgia—Donepezil—Alzheimer's disease	0.000556	0.00319	CcSEcCtD
Vemurafenib—Body temperature increased—Galantamine—Alzheimer's disease	0.000543	0.00312	CcSEcCtD
Vemurafenib—RAF1—nervous system—Alzheimer's disease	0.000531	0.0516	CbGeAlD
Vemurafenib—Infection—Donepezil—Alzheimer's disease	0.000529	0.00304	CcSEcCtD
Vemurafenib—Nervous system disorder—Donepezil—Alzheimer's disease	0.000522	0.003	CcSEcCtD
Vemurafenib—Cough—Memantine—Alzheimer's disease	0.000517	0.00297	CcSEcCtD
Vemurafenib—RAF1—central nervous system—Alzheimer's disease	0.000511	0.0497	CbGeAlD
Vemurafenib—Hypersensitivity—Galantamine—Alzheimer's disease	0.000506	0.00291	CcSEcCtD
Vemurafenib—Cough—Rivastigmine—Alzheimer's disease	0.000506	0.00291	CcSEcCtD
Vemurafenib—Arthralgia—Memantine—Alzheimer's disease	0.000505	0.0029	CcSEcCtD
Vemurafenib—Myalgia—Memantine—Alzheimer's disease	0.000505	0.0029	CcSEcCtD
Vemurafenib—RAF1—cerebellum—Alzheimer's disease	0.0005	0.0486	CbGeAlD
Vemurafenib—Hypotension—Donepezil—Alzheimer's disease	0.000498	0.00286	CcSEcCtD
Vemurafenib—Myalgia—Rivastigmine—Alzheimer's disease	0.000494	0.00283	CcSEcCtD
Vemurafenib—Arthralgia—Rivastigmine—Alzheimer's disease	0.000494	0.00283	CcSEcCtD
Vemurafenib—Asthenia—Galantamine—Alzheimer's disease	0.000493	0.00283	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.00049	0.00282	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000485	0.00279	CcSEcCtD
Vemurafenib—Infection—Memantine—Alzheimer's disease	0.00048	0.00276	CcSEcCtD
Vemurafenib—Nervous system disorder—Memantine—Alzheimer's disease	0.000474	0.00272	CcSEcCtD
Vemurafenib—Diarrhoea—Galantamine—Alzheimer's disease	0.00047	0.0027	CcSEcCtD
Vemurafenib—Infection—Rivastigmine—Alzheimer's disease	0.00047	0.0027	CcSEcCtD
Vemurafenib—Skin disorder—Memantine—Alzheimer's disease	0.00047	0.0027	CcSEcCtD
Vemurafenib—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000464	0.00266	CcSEcCtD
Vemurafenib—Decreased appetite—Donepezil—Alzheimer's disease	0.000463	0.00266	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.00046	0.00264	CcSEcCtD
Vemurafenib—Skin disorder—Rivastigmine—Alzheimer's disease	0.00046	0.00264	CcSEcCtD
Vemurafenib—Fatigue—Donepezil—Alzheimer's disease	0.000459	0.00264	CcSEcCtD
Vemurafenib—Constipation—Donepezil—Alzheimer's disease	0.000456	0.00262	CcSEcCtD
Vemurafenib—Dizziness—Galantamine—Alzheimer's disease	0.000455	0.00261	CcSEcCtD
Vemurafenib—Hypotension—Memantine—Alzheimer's disease	0.000452	0.0026	CcSEcCtD
Vemurafenib—ABCC1—telencephalon—Alzheimer's disease	0.000449	0.0437	CbGeAlD
Vemurafenib—Hypotension—Rivastigmine—Alzheimer's disease	0.000442	0.00254	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000441	0.00253	CcSEcCtD
Vemurafenib—Vomiting—Galantamine—Alzheimer's disease	0.000437	0.00251	CcSEcCtD
Vemurafenib—Rash—Galantamine—Alzheimer's disease	0.000433	0.00249	CcSEcCtD
Vemurafenib—Dermatitis—Galantamine—Alzheimer's disease	0.000433	0.00249	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000431	0.00248	CcSEcCtD
Vemurafenib—Headache—Galantamine—Alzheimer's disease	0.000431	0.00247	CcSEcCtD
Vemurafenib—Body temperature increased—Donepezil—Alzheimer's disease	0.000421	0.00242	CcSEcCtD
Vemurafenib—Decreased appetite—Memantine—Alzheimer's disease	0.00042	0.00241	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000418	0.0024	CcSEcCtD
Vemurafenib—Fatigue—Memantine—Alzheimer's disease	0.000417	0.00239	CcSEcCtD
Vemurafenib—Constipation—Memantine—Alzheimer's disease	0.000414	0.00238	CcSEcCtD
Vemurafenib—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000411	0.00236	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000408	0.00235	CcSEcCtD
Vemurafenib—Nausea—Galantamine—Alzheimer's disease	0.000408	0.00234	CcSEcCtD
Vemurafenib—Fatigue—Rivastigmine—Alzheimer's disease	0.000408	0.00234	CcSEcCtD
Vemurafenib—RAF1—brain—Alzheimer's disease	0.000406	0.0395	CbGeAlD
Vemurafenib—Constipation—Rivastigmine—Alzheimer's disease	0.000405	0.00232	CcSEcCtD
Vemurafenib—Hypersensitivity—Donepezil—Alzheimer's disease	0.000392	0.00225	CcSEcCtD
Vemurafenib—Body temperature increased—Memantine—Alzheimer's disease	0.000382	0.0022	CcSEcCtD
Vemurafenib—Asthenia—Donepezil—Alzheimer's disease	0.000382	0.00219	CcSEcCtD
Vemurafenib—Pruritus—Donepezil—Alzheimer's disease	0.000377	0.00216	CcSEcCtD
Vemurafenib—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000374	0.00215	CcSEcCtD
Vemurafenib—ABCG2—telencephalon—Alzheimer's disease	0.000372	0.0362	CbGeAlD
Vemurafenib—ORM1—nervous system—Alzheimer's disease	0.000367	0.0356	CbGeAlD
Vemurafenib—Diarrhoea—Donepezil—Alzheimer's disease	0.000364	0.00209	CcSEcCtD
Vemurafenib—Hypersensitivity—Memantine—Alzheimer's disease	0.000356	0.00205	CcSEcCtD
Vemurafenib—ORM1—central nervous system—Alzheimer's disease	0.000353	0.0343	CbGeAlD
Vemurafenib—Dizziness—Donepezil—Alzheimer's disease	0.000352	0.00202	CcSEcCtD
Vemurafenib—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000349	0.002	CcSEcCtD
Vemurafenib—Asthenia—Memantine—Alzheimer's disease	0.000347	0.00199	CcSEcCtD
Vemurafenib—Pruritus—Memantine—Alzheimer's disease	0.000342	0.00197	CcSEcCtD
Vemurafenib—Asthenia—Rivastigmine—Alzheimer's disease	0.000339	0.00195	CcSEcCtD
Vemurafenib—Vomiting—Donepezil—Alzheimer's disease	0.000339	0.00195	CcSEcCtD
Vemurafenib—Rash—Donepezil—Alzheimer's disease	0.000336	0.00193	CcSEcCtD
Vemurafenib—Dermatitis—Donepezil—Alzheimer's disease	0.000336	0.00193	CcSEcCtD
Vemurafenib—Pruritus—Rivastigmine—Alzheimer's disease	0.000335	0.00192	CcSEcCtD
Vemurafenib—Headache—Donepezil—Alzheimer's disease	0.000334	0.00192	CcSEcCtD
Vemurafenib—Diarrhoea—Memantine—Alzheimer's disease	0.000331	0.0019	CcSEcCtD
Vemurafenib—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000324	0.00186	CcSEcCtD
Vemurafenib—Dizziness—Memantine—Alzheimer's disease	0.00032	0.00184	CcSEcCtD
Vemurafenib—Nausea—Donepezil—Alzheimer's disease	0.000316	0.00182	CcSEcCtD
Vemurafenib—Dizziness—Rivastigmine—Alzheimer's disease	0.000313	0.0018	CcSEcCtD
Vemurafenib—Vomiting—Memantine—Alzheimer's disease	0.000308	0.00177	CcSEcCtD
Vemurafenib—Rash—Memantine—Alzheimer's disease	0.000305	0.00175	CcSEcCtD
Vemurafenib—Dermatitis—Memantine—Alzheimer's disease	0.000305	0.00175	CcSEcCtD
Vemurafenib—Headache—Memantine—Alzheimer's disease	0.000303	0.00174	CcSEcCtD
Vemurafenib—Vomiting—Rivastigmine—Alzheimer's disease	0.000301	0.00173	CcSEcCtD
Vemurafenib—Rash—Rivastigmine—Alzheimer's disease	0.000298	0.00171	CcSEcCtD
Vemurafenib—Dermatitis—Rivastigmine—Alzheimer's disease	0.000298	0.00171	CcSEcCtD
Vemurafenib—Headache—Rivastigmine—Alzheimer's disease	0.000296	0.0017	CcSEcCtD
Vemurafenib—Nausea—Memantine—Alzheimer's disease	0.000287	0.00165	CcSEcCtD
Vemurafenib—Nausea—Rivastigmine—Alzheimer's disease	0.000281	0.00161	CcSEcCtD
Vemurafenib—CYP2D6—forebrain—Alzheimer's disease	0.000277	0.027	CbGeAlD
Vemurafenib—CYP2D6—telencephalon—Alzheimer's disease	0.000255	0.0248	CbGeAlD
Vemurafenib—ABCC1—cerebellum—Alzheimer's disease	0.00025	0.0243	CbGeAlD
Vemurafenib—ALB—brain—Alzheimer's disease	0.000246	0.0239	CbGeAlD
Vemurafenib—ABCG2—cerebellum—Alzheimer's disease	0.000207	0.0201	CbGeAlD
Vemurafenib—ABCC1—brain—Alzheimer's disease	0.000203	0.0197	CbGeAlD
Vemurafenib—ABCG2—brain—Alzheimer's disease	0.000168	0.0163	CbGeAlD
Vemurafenib—CYP3A4—nervous system—Alzheimer's disease	0.000153	0.0149	CbGeAlD
Vemurafenib—CYP2D6—nervous system—Alzheimer's disease	0.000151	0.0146	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—Alzheimer's disease	0.000147	0.0143	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—Alzheimer's disease	0.000145	0.0141	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—Alzheimer's disease	0.000142	0.0138	CbGeAlD
Vemurafenib—CYP2D6—brain—Alzheimer's disease	0.000115	0.0112	CbGeAlD
Vemurafenib—BRAF—Disease—NOS3—Alzheimer's disease	1.33e-05	8.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HMOX1—Alzheimer's disease	1.33e-05	8.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—Alzheimer's disease	1.32e-05	8.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—Alzheimer's disease	1.32e-05	8.33e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—Alzheimer's disease	1.31e-05	8.29e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—Alzheimer's disease	1.31e-05	8.26e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MAOB—Alzheimer's disease	1.31e-05	8.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—F2—Alzheimer's disease	1.29e-05	8.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—Alzheimer's disease	1.28e-05	8.09e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLD3—Alzheimer's disease	1.28e-05	8.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—Alzheimer's disease	1.27e-05	8.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NGFR—Alzheimer's disease	1.26e-05	7.95e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GAPDH—Alzheimer's disease	1.26e-05	7.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—Alzheimer's disease	1.26e-05	7.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CREB1—Alzheimer's disease	1.25e-05	7.9e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CALM1—Alzheimer's disease	1.25e-05	7.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—LEP—Alzheimer's disease	1.24e-05	7.85e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—Alzheimer's disease	1.24e-05	7.85e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	1.24e-05	7.85e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CALM1—Alzheimer's disease	1.23e-05	7.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CAV1—Alzheimer's disease	1.23e-05	7.78e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	1.23e-05	7.78e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADAM10—Alzheimer's disease	1.23e-05	7.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—Alzheimer's disease	1.23e-05	7.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSD17B10—Alzheimer's disease	1.23e-05	7.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—Alzheimer's disease	1.22e-05	7.73e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CALM1—Alzheimer's disease	1.22e-05	7.71e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—Alzheimer's disease	1.22e-05	7.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CAV1—Alzheimer's disease	1.22e-05	7.68e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—Alzheimer's disease	1.22e-05	7.68e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—LPL—Alzheimer's disease	1.22e-05	7.68e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—A2M—Alzheimer's disease	1.21e-05	7.67e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CAV1—Alzheimer's disease	1.21e-05	7.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—Alzheimer's disease	1.2e-05	7.55e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ESR1—Alzheimer's disease	1.19e-05	7.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP46A1—Alzheimer's disease	1.18e-05	7.46e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARGC1A—Alzheimer's disease	1.17e-05	7.42e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—F2—Alzheimer's disease	1.17e-05	7.4e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HMOX1—Alzheimer's disease	1.17e-05	7.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—S100B—Alzheimer's disease	1.16e-05	7.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—GSK3B—Alzheimer's disease	1.15e-05	7.27e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOTCH1—Alzheimer's disease	1.15e-05	7.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—Alzheimer's disease	1.14e-05	7.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CREB1—Alzheimer's disease	1.14e-05	7.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ND1—Alzheimer's disease	1.14e-05	7.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—Alzheimer's disease	1.14e-05	7.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—Alzheimer's disease	1.13e-05	7.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOTCH1—Alzheimer's disease	1.13e-05	7.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IGF1—Alzheimer's disease	1.13e-05	7.12e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CHAT—Alzheimer's disease	1.12e-05	7.1e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TPI1—Alzheimer's disease	1.12e-05	7.1e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOTCH1—Alzheimer's disease	1.12e-05	7.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF2—Alzheimer's disease	1.11e-05	6.99e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—Alzheimer's disease	1.09e-05	6.92e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	1.08e-05	6.84e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MAOB—Alzheimer's disease	1.08e-05	6.81e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GSK3B—Alzheimer's disease	1.08e-05	6.8e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—LPL—Alzheimer's disease	1.07e-05	6.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1R—Alzheimer's disease	1.07e-05	6.76e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CREB1—Alzheimer's disease	1.07e-05	6.74e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—GSK3B—Alzheimer's disease	1.06e-05	6.72e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—INS—Alzheimer's disease	1.06e-05	6.71e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ACHE—Alzheimer's disease	1.06e-05	6.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CREB1—Alzheimer's disease	1.05e-05	6.66e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—GSK3B—Alzheimer's disease	1.05e-05	6.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—INS—Alzheimer's disease	1.05e-05	6.63e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CREB1—Alzheimer's disease	1.05e-05	6.6e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—Alzheimer's disease	1.04e-05	6.6e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—INPP5D—Alzheimer's disease	1.04e-05	6.59e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—INS—Alzheimer's disease	1.04e-05	6.57e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GAPDH—Alzheimer's disease	1.04e-05	6.56e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	1.04e-05	6.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—Alzheimer's disease	1.03e-05	6.53e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1—Alzheimer's disease	1.03e-05	6.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LPL—Alzheimer's disease	1.03e-05	6.48e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CALM1—Alzheimer's disease	1.02e-05	6.46e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—Alzheimer's disease	1.02e-05	6.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—Alzheimer's disease	1.02e-05	6.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MEF2C—Alzheimer's disease	1.02e-05	6.42e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAV1—Alzheimer's disease	1.01e-05	6.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—A2M—Alzheimer's disease	1e-05	6.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PRKCG—Alzheimer's disease	9.97e-06	6.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS1—Alzheimer's disease	9.89e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO1—Alzheimer's disease	9.89e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NGF—Alzheimer's disease	9.71e-06	6.14e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2D6—Alzheimer's disease	9.7e-06	6.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—Alzheimer's disease	9.65e-06	6.1e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—Alzheimer's disease	9.63e-06	6.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2—Alzheimer's disease	9.59e-06	6.06e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CHAT—Alzheimer's disease	9.52e-06	6.02e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TPI1—Alzheimer's disease	9.52e-06	6.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR5—Alzheimer's disease	9.45e-06	5.97e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—Alzheimer's disease	9.31e-06	5.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR2A—Alzheimer's disease	9.25e-06	5.84e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BCHE—Alzheimer's disease	9.2e-06	5.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—Alzheimer's disease	9.2e-06	5.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MAOB—Alzheimer's disease	9.13e-06	5.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—Alzheimer's disease	9.12e-06	5.76e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—Alzheimer's disease	9.12e-06	5.76e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CALM1—Alzheimer's disease	9e-06	5.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—Alzheimer's disease	8.97e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—Alzheimer's disease	8.9e-06	5.62e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAV1—Alzheimer's disease	8.88e-06	5.61e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—Alzheimer's disease	8.88e-06	5.61e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—Alzheimer's disease	8.79e-06	5.55e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GAPDH—Alzheimer's disease	8.79e-06	5.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—Alzheimer's disease	8.73e-06	5.52e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ACHE—Alzheimer's disease	8.72e-06	5.51e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—INS—Alzheimer's disease	8.7e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	8.69e-06	5.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLCB1—Alzheimer's disease	8.68e-06	5.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CALM1—Alzheimer's disease	8.63e-06	5.45e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	8.62e-06	5.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	8.61e-06	5.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—Alzheimer's disease	8.6e-06	5.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—Alzheimer's disease	8.6e-06	5.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—Alzheimer's disease	8.52e-06	5.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CAV1—Alzheimer's disease	8.52e-06	5.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	8.51e-06	5.38e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—A2M—Alzheimer's disease	8.49e-06	5.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—Alzheimer's disease	8.48e-06	5.35e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCA1—Alzheimer's disease	8.41e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—Alzheimer's disease	8.41e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—Alzheimer's disease	8.34e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ESR1—Alzheimer's disease	8.21e-06	5.19e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	8.17e-06	5.16e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO1—Alzheimer's disease	8.17e-06	5.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—F2—Alzheimer's disease	8.11e-06	5.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—Alzheimer's disease	7.93e-06	5.01e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—Alzheimer's disease	7.9e-06	4.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—Alzheimer's disease	7.86e-06	4.97e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—Alzheimer's disease	7.81e-06	4.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK8—Alzheimer's disease	7.77e-06	4.91e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—INS—Alzheimer's disease	7.66e-06	4.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—Alzheimer's disease	7.63e-06	4.82e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BCHE—Alzheimer's disease	7.59e-06	4.8e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	7.57e-06	4.78e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—Alzheimer's disease	7.55e-06	4.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GSK3B—Alzheimer's disease	7.44e-06	4.7e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ACHE—Alzheimer's disease	7.38e-06	4.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREB1—Alzheimer's disease	7.38e-06	4.67e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—Alzheimer's disease	7.37e-06	4.65e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CHAT—Alzheimer's disease	7.35e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TPI1—Alzheimer's disease	7.35e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INS—Alzheimer's disease	7.34e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—INPP5D—Alzheimer's disease	7.3e-06	4.61e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK8—Alzheimer's disease	7.26e-06	4.59e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARGC1A—Alzheimer's disease	7.25e-06	4.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—Alzheimer's disease	7.22e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—Alzheimer's disease	7.22e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	7.16e-06	4.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—Alzheimer's disease	7.1e-06	4.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MAOB—Alzheimer's disease	7.05e-06	4.45e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—Alzheimer's disease	6.98e-06	4.41e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	6.94e-06	4.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO1—Alzheimer's disease	6.92e-06	4.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	6.92e-06	4.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	6.79e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	6.78e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—Alzheimer's disease	6.76e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—Alzheimer's disease	6.72e-06	4.24e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—Alzheimer's disease	6.71e-06	4.24e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—Alzheimer's disease	6.62e-06	4.18e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LPL—Alzheimer's disease	6.6e-06	4.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—A2M—Alzheimer's disease	6.55e-06	4.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—Alzheimer's disease	6.44e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BCHE—Alzheimer's disease	6.43e-06	4.06e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—Alzheimer's disease	6.15e-06	3.89e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—Alzheimer's disease	6.14e-06	3.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—Alzheimer's disease	6.11e-06	3.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—Alzheimer's disease	6.08e-06	3.84e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	6.07e-06	3.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—Alzheimer's disease	6.03e-06	3.81e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	5.99e-06	3.78e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	5.96e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	5.95e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—Alzheimer's disease	5.94e-06	3.75e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	5.88e-06	3.72e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACHE—Alzheimer's disease	5.7e-06	3.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	5.63e-06	3.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—Alzheimer's disease	5.56e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CALM1—Alzheimer's disease	5.55e-06	3.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—Alzheimer's disease	5.53e-06	3.5e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAV1—Alzheimer's disease	5.48e-06	3.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—Alzheimer's disease	5.47e-06	3.45e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LPL—Alzheimer's disease	5.45e-06	3.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—Alzheimer's disease	5.43e-06	3.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	5.34e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO1—Alzheimer's disease	5.34e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	5.24e-06	3.31e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	5.07e-06	3.2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—Alzheimer's disease	5.07e-06	3.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	5.05e-06	3.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK8—Alzheimer's disease	5.02e-06	3.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—Alzheimer's disease	5.01e-06	3.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCHE—Alzheimer's disease	4.96e-06	3.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—Alzheimer's disease	4.96e-06	3.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	4.91e-06	3.1e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—Alzheimer's disease	4.82e-06	3.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—INS—Alzheimer's disease	4.73e-06	2.99e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—Alzheimer's disease	4.7e-06	2.97e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	4.68e-06	2.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—Alzheimer's disease	4.64e-06	2.93e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—Alzheimer's disease	4.64e-06	2.93e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPL—Alzheimer's disease	4.62e-06	2.92e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CALM1—Alzheimer's disease	4.58e-06	2.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—Alzheimer's disease	4.58e-06	2.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—Alzheimer's disease	4.58e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—Alzheimer's disease	4.57e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—Alzheimer's disease	4.54e-06	2.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	4.54e-06	2.87e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAV1—Alzheimer's disease	4.53e-06	2.86e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—Alzheimer's disease	4.28e-06	2.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—Alzheimer's disease	4.26e-06	2.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—Alzheimer's disease	4.23e-06	2.67e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—Alzheimer's disease	4.19e-06	2.65e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	4.16e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—Alzheimer's disease	4.14e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—Alzheimer's disease	3.98e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	3.91e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—INS—Alzheimer's disease	3.9e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	3.9e-06	2.46e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CALM1—Alzheimer's disease	3.88e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—Alzheimer's disease	3.87e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAV1—Alzheimer's disease	3.83e-06	2.42e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—Alzheimer's disease	3.79e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPL—Alzheimer's disease	3.56e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—Alzheimer's disease	3.51e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—Alzheimer's disease	3.51e-06	2.21e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—Alzheimer's disease	3.42e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—Alzheimer's disease	3.37e-06	2.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—INS—Alzheimer's disease	3.31e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—Alzheimer's disease	3.21e-06	2.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	3.21e-06	2.03e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	3.13e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—Alzheimer's disease	3.09e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CALM1—Alzheimer's disease	3e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—Alzheimer's disease	2.99e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—Alzheimer's disease	2.96e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAV1—Alzheimer's disease	2.96e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—Alzheimer's disease	2.9e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	2.65e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—Alzheimer's disease	2.6e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—INS—Alzheimer's disease	2.55e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—Alzheimer's disease	2.24e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	2.05e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—Alzheimer's disease	1.91e-06	1.2e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—Alzheimer's disease	1.57e-06	9.94e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—Alzheimer's disease	1.33e-06	8.42e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—Alzheimer's disease	1.03e-06	6.5e-06	CbGpPWpGaD
